EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/ΔNS2/1030s in RSV-Seronegative Young Children

Ruth A Karron, Cindy Luongo, Suzanne Woods, Jennifer Oliva, Peter L Collins, Ursula J Buchholz, RSVPed Team

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiad281 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Ruth A Karron und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) is the leading cause of pediatric lower respiratory illness (LRI) and a vaccine for immunization of children is needed. RSV/6120/ΔNS2/1030s is a cDNA-derived live-vaccine candidate attenuated by deletion of the interferon antagonist NS2 gene and the genetically stabilized 1030s missense polymerase mutation in the polymerase, conferring temperature sensitivity.

Methods

A single intranasal dose of RSV/6120/ΔNS2/1030s was evaluated in a double-blind, placebo-controlled trial (vaccine to placebo ratio, 2:1) at 105.7 plaque-forming units (PFU) in 15 RSV-seropositive 12- to 59-month-old children, and at 105 PFU in 30 RSV-seronegative 6- to 24-month-old children.

Results

RSV/6120/ΔNS2/1030s infected 100% of RSV-seronegative vaccinees and was immunogenic (geometric mean RSV plaque-reduction neutralizing antibody titer [RSV-PRNT], 1:91) and genetically stable. Mild rhinorrhea was detected more frequently in vaccinees (18/20 vaccinees vs 4/10 placebo recipients, P = .007), and LRI occurred in 1 vaccinee during a period when only vaccine virus was detected. Following the RSV season, 5 of 16 vaccinees had ≥4-fold rises in RSV-PRNT with significantly higher titers than 4 of 10 placebo recipients with rises (1:1992 vs 1:274, P = .02). Thus, RSV/6120/ΔNS2/1030s primed for substantial anamnestic neutralizing antibody responses following naturally acquired RSV infection.

Conclusions

RSV/6120/ΔNS2/1030s is immunogenic and genetically stable in RSV-seronegative children, but the frequency of rhinorrhea in vaccinees exceeded that in placebo recipients. Clinical Trials Registration NCT03387137.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsHumansChildChild, PreschoolInfantAntibodies, ViralAntibodies, NeutralizingVaccines, AttenuatedRhinorrhea

Stichwörter der Autor:innen

RSVintranasal vaccinelive-attenuatedpediatricvaccine

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, NeutralizingVaccines, Attenuated

Autor:innen und Institutionen

  • Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Förderung

  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • Sanofi

Zitieren

APA

Karron, R. A., Luongo, C., Woods, S., Oliva, J., Collins, P. L., Buchholz, U. J., & RSVPed Team (2024). Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/ΔNS2/1030s in RSV-Seronegative Young Children. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad281

Vancouver

Karron RA, Luongo C, Woods S, Oliva J, Collins PL, Buchholz UJ, et al. Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/ΔNS2/1030s in RSV-Seronegative Young Children. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad281

BibTeX
@article{Karron2024,
  author = {Karron, Ruth A and Luongo, Cindy and Woods, Suzanne and Oliva, Jennifer and Collins, Peter L and Buchholz, Ursula J and RSVPed Team, RSVPed Team},
  title = {Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/ΔNS2/1030s in RSV-Seronegative Young Children},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiad281}
}
Kostenlos starten →